Session Name: Poster Session C: Lung: All Topics
Session Type: Poster Session
Date: Saturday, May 30, 2020
Session Time: 3:15pm-4:00pm
Presentation Time: 3:30pm-4:00pm
*Purpose: The treatment of patients with end-stage idiopathic pulmonary fibrosis (IPF) and lung cancer (LC) is a difficult task, and it remains questionable whether LC should be treated. Lung transplantation is an effective treatment for IPF. However, little knowledge indicates the effectiveness of the treatment for IPF-LC. The purpose of this study was to retrospectively evaluate the safety and clinical outcomes of lung transplantation for patients with advanced IPF-LC .
*Methods: A total of eight patients with advanced IPF-LC were enrolled in this retrospective study. The diagnosis of IPF-LC is based on pathological confirmation. Preoperative evaluation mainly includes high-resolution computed tomography of the chest (HRCT), arterial blood gas analysis, pulmonary function test, 6-minute walk test, cardiac echocardiography, skull CT, abdominal CT and positron emission tomography and computed tomography.
*Results: Of these 8 patients,7 were over 60 years old, and 6 had a history of smoking. Coughing in 7 cases, spitting in 5 cases, and all the cases had dyspnea. There were 3 cases of squamous cell carcinoma, 3 cases of adenocarcinoma, 1 case of small cell lung cancer, and 1 case of carcinoid. 4 patients received single lung transplants and 4 received double lung transplants. There were no obvious intraoperative complications, and 7 patients needed intraoperative extracorporeal membrane oxygenation (ECMO) support. Two cases were severely infected, one died within 30 days after operation. Another one died of severe arrhythmia on the 4th post-operation day. The one-year survival rate after transplantation is 75%. So far there have been no signs of tumor recurrence found.
*Conclusions: After strict preoperative assessment of lung transplantation, early lung cancer with end-stage IPF can be treated with lung transplantation. However, strict screening must be performed, and patients must be informed of the prognosis and the possibility of tumor regeneration.
To cite this abstract in AMA style:Zhang J, Liu D, Chen J. Clinical Evaluation of Lung Transplantation for End-Stage Idiopathic Pulmonary Fibrosis Patients with Lung Cancer [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/clinical-evaluation-of-lung-transplantation-for-end-stage-idiopathic-pulmonary-fibrosis-patients-with-lung-cancer/. Accessed December 6, 2023.
« Back to 2020 American Transplant Congress